Timolumab for Primary Sclerosing Cholangitis
Timolumab is currently being developed to treat PSC. Timolumab is given by injection into the vein which blocks a molecule called VAP-1 from working. VAP-1 helps immune cells enter areas of inflammation (such as the bile ducts in PSC) where they can further contribute to inflammation. By blocking this process, timolumab has the potential to prevent some of the inflammation in PSC and slow the progress of the disease.
Tenapanor for Irritable Bowel Syndrome with Constipation
Irritable bowel syndrome with constipation (IBS-C) is a common condition that affects the digestive system (the gut). Symptoms may include stomach cramps, bloating and constipation. The exact cause is unknown, and IBS-C is often a lifelong condition. While there is no cure, dietary changes and the use of medication can often help control symptoms. IBS-C …
Volixibat for non-alcoholic steatohepatitis (NASH)
Currently, there are no approved therapies for the treatment of NASH, but doctors recommend dietary changes and exercise to prevent or slow disease progression. Volixibat is a new experimental once-daily oral tablet that may improve NASH by targeting and blocking a protein (apical sodium-dependent bile acid transporter) found in the liver. This is thought to …
A4250 for progressive familial intrahepatic cholestasis
Progressive familial intrahepatic cholestasis (PFIC) is a rare, inherited condition that usually begins in infancy. The condition affects the liver, hindering or stopping the flow of bile from the liver. Bile flow is needed for fats, nutrients and vitamins to be absorbed into the body, and also to help the body get rid of toxins. …
Seladelpar for primary biliary cirrhosis – second or subsequent line
Primary biliary cirrhosis (PBC), is a long-term liver disease in which the pipes (ducts) that transports bile in the liver become damaged. PBC causes the build-up of bile in the liver and eventually may lead to scarring. Nine out of ten people with PBC are women. The exact cause of PBC is not known, although …
Cenicriviroc for non-alcoholic steatohepatitis (NASH)
Cenicriviroc is a new experimental once-daily oral tablet that may improve liver fibrosis in patients with NASH by targeting and blocking the immune and inflammatory pathways responsible for fibrosis. If licensed, cenicriviroc has the potential to establish itself as both a single-agent and as a cornerstone treatment for NASH.
Liprotamase (Sollpura) for exocrine pancreatic insufficiency due to cystic fibrosis
Liprotamase is a new drug for the treatment of exocrine pancreatic insufficiency (EPI), a condition where the pancreas does not produce enough enzymes for digesting fat, carbohydrates and proteins. EPI is common in patients who have cystic fibrosis (CF), which is the most common inherited disease in the UK.Liprotamase works by replacing the lacking pancreatic …
Budesonide orodispersible tablet for eosinophilic oesophagitis – first line
Budesonide orodispersible tablets are a new formulation of budesonide to treat eosinophilic oesophagitis in adults. Eosinophilic oesophagitis is an inflammatory condition that causes problems with eating and swallowing. Budesonide orodispersible tablets are dissolved in the mouth and slowly swallowed. Some studies have suggested that budesonide may reduce the inflammatory reaction that causes the symptoms of …